Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — Corporate Update (July 2020)
10 slides from Marinomed Biotech's corporate update, July 2020
Slide 1: Update on Carragelose: First Data Show Neutralizing Effect on SARS-CoV-2
Update on Carragelose® First Data Show Neutralizing Effect on SARS-CoV-2 July 2020
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Mode of Action of Carragelose
Mode of Action of Carragelose® Infection and Blocking viral Virus entry Viral clearance replication attachment ◼ Colds are caused by ◼ Cold viruses bind to ◼ Carragelose creates a ◼ Clotted viruses leave >200 different the mucosal surfaces protective viscous layer the body via natural respiratory vi
Slide 4: The activity of Carragelose against SARS-CoV-2 in comparison with other respiratory viruses
The activity of Carragelose® against SARS-CoV-2 in comparison with other respiratory viruses Virus Strain IC50 Carragelose® SARS-CoV-2 < 5µg/ml Human Rhinovirs 1a 1-10 µg/ml Human Rhinovirus 8 1-10 µg/ml Coxsackie A10 2-20 µg/ml Respiratory Syncytial Virus 1-10 µg/ml Human Coronavirus OC43 < 1 µg/ml
Slide 5: Virus Neutralization Assay
Virus Neutralization Assay 35 30 25 Luciferase Units 20 15 10 5 0 Negative Positive 400 µg/mL 400 µg/mL Control Control Carragelose CMC Carragelose is highly active in virus neutralization assay preventing infection of cells compared to controls 5
Slide 6: Carragelose Dose Dependent Activity Against SARS-CoV-2
Carragelose® Dose Dependent Activity Against SARS-COV-2 140 120 % infection control 100 80 60 40 20 0 -20 Negative 33 10 1 Positive 100 3.3 0.33 HPMC Control Control µg/ml Higher concentrations of Carragelose® have better control of infection 6
Slide 7: Comparison of Different Polymers Against SARS-CoV-2
Comparison of Different Polymers Against SARS-COV-2 160 140 % infection control 120 100 80 60 40 20 0 100 µg/ml 10 µg/ml 1 µg/ml Iota Carragenan ( ) yields excellent results already at lower doses and is at the same time safe 7
Slide 8: Apply Same Technology to Lungs to Succeed in Protecting Entire Respiratory Tract
Apply Same Technology to Lungs to Succeed in Protecting Entire Respiratory Tract 1 Nasal products Marketed 1 2 Throat products 2 Marketed 3 Lung products ▪ Planning clinical testing of inhaled solution containing Carragelose® against virally-induced 3 pneumonia ▪ First efficacy results expected with
Slide 9: Conclusion
Conclusion ▪ In-vitro data underscore protection Carragelose® provides against ▪ SARS-CoV-2 ▪ Multitude of respiratory viruses ▪ Important as we continue to deal with COVID-19 and move into cold and flu season 9
Slide 10: www.marinomed.com
: Orrarino www.marinomed.com